The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 61, Issue 3, 2008, Pages 391-397

  Karapanagiotou, Eleni M ^a   Tsochatzis, Emmanouil A ^a   Dilana, Kalliopi D ^a   Tourkantonis, Ioannis ^a   Gratsias, Ioannis ^a   Syrigos, Konstantinos N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adiponectin; Leptin; Non small cell lung cancer; Resistin; Weight loss

Indexed keywords

ADIPONECTIN; LEPTIN; PLATINUM DERIVATIVE; RESISTIN; TAXANE DERIVATIVE;

ADIPOSE TISSUE; ADULT; ADVANCED CANCER; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; WEIGHT REDUCTION;

ADIPONECTIN; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEPTIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESISTIN; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 50849096645     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.01.018     Document Type: Article

References (33)

1. Koerner A., Kratzsch J., and Kiess W. Adipocytokines: leptin - the classical, resistin - the controversial, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19 4 (2005) 525-546
2. Meier U., and Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50 9 (2004) 1511-1525
3. Steppan C.M., and Lazar M.A. The current biology of resistin. J Intern Med 255 4 (2004) 439-447
4. Tsochatzis E., Papatheodoridis G.V., and Archimandritis A.J. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 101 11 (2006) 2629-2640
5. Deans C., and Wigmore S.J. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8 3 (2005) 265-269
6. O'Gorman P., McMillan D.C., and McArdle C.S. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37 1 (2000) 36-40
7. Scott H.R., McMillan D.C., Forrest L.M., Brown D.J., McArdle C.S., and Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87 3 (2002) 264-267
8. Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, Eisen T, O'brien ME, Cunningham D, Andreyev HJ. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer; 2006.
9. Martin F., Santolaria F., Batista N., Milena A., Gonzalez-Reimers E., Brito M.J., et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11 1 (1999) 80-86
10. McMillan D.C., Scott H.R., Watson W.S., Preston T., Milroy R., and McArdle C.S. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 31 2 (1998) 101-105
11. Staal-van den Brekel A.J., Dentener M.A., Schols A.M., Buurman W.A., and Wouters E.F. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13 10 (1995) 2600-2605
12. Sobin L.H., and Fleming I.D. TNM Classification of Malignant Tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80 9 (1997) 1803-1804
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
14. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 6 (1982) 649-655
15. Arpaci F., Yilmaz M.I., Ozet A., Ayta H., Ozturk B., Komurcu S., et al. Low serum leptin level in colon cancer patients without significant weight loss. Tumori 88 2 (2002) 147-149
16. Brown D.R., Berkowitz D.E., and Breslow M.J. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab 86 1 (2001) 162-166
17. Dulger H., Alici S., Sekeroglu M.R., Erkog R., Ozbek H., Noyan T., et al. Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int J Clin Pract 58 6 (2004) 545-549
18. Mantovani G., Maccio A., Mura L., Massa E., Mudu M.C., Mulas C., et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78 10 (2000) 554-561
19. Aleman M.R., Santolaria F., Batista N., de L.V., Gonzalez-Reimers E., Milena A., et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition?. Cytokine 19 1 (2002) 21-26
20. Jamieson N.B., Brown D.J., Michael W.A., and McMillan D.C. Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine 27 2/3 (2004) 90-92
21. Tas F., Duranyildiz D., Argon A., Oguz H., Camlica H., Yasasever V., et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 22 4 (2005) 353-358
22. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285 3 (2003) E527-E533
23. Wang B., Jenkins J.R., and Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab 288 4 (2005) E731-E740
24. Gomez-Ambrosi J., and Fruhbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases?. Ann Intern Med 135 4 (2001) 306-307
25. Wolfe B.E., Jimerson D.C., Orlova C., and Mantzoros C.S. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf) 61 3 (2004) 332-338
26. Pannacciulli N., Vettor R., Milan G., Granzotto M., Catucci A., Federspil G., et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 88 4 (2003) 1748-1752
27. Staiger H., Tschritter O., Machann J., Thamer C., Fritsche A., Maerker E., et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 11 3 (2003) 368-372
28. Simons J.P., Schols A.M., Campfield L.A., Wouters E.F., and Saris W.H. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 93 3 (1997) 273-277
29. Bolukbas F.F., Kilic H., Bolukbas C., Gumus M., Horoz M., Turhal N.S., et al. Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 4 (2004) 29
30. Wallace A.M., Sattar N., and McMillan D.C. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res 4 12 (1998) 2977-2979
31. Wolf I., Sadetzki S., Kanety H., Kundel Y., Pariente C., Epstein N., et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106 4 (2006) 966-973
32. Douglas R.G., and Shaw J.H. Metabolic effects of cancer. Br J Surg 77 3 (1990) 246-254
33. Shaw J.H., Humberstone D.A., Douglas R.G., and Koea J. Leucine kinetics in patients with benign disease, non-weight-losing cancer, and cancer cachexia: studies at the whole-body and tissue level and the response to nutritional support. Surgery 109 1 (1991) 37-50